ImmunoGen

-$0.07 (-1.98%) Today

$0.00 (0.00%) As of 9:59 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ImmunoGen and other ETFs, options, and stocks.

About IMGN

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151.

CEO

Mark Joseph Enyedy

Employees

106

Headquarters

Waltham, Massachusetts

Founded

1981

IMGN Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

5.57M

High today

$3.63

Low today

$3.36

Open price

$3.53

Volume

3.26M

52 Week high

$7.77

52 Week low

$3.36

IMGN News

MarketWatchMay 23

ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy

Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an applicatio

Analyst ratings

Buy

70%

Hold

30%

Sell

IMGN Earnings

-$1.71

-$1.09

-$0.46

$0.16

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Actual

Expected Jul 29, Pre-Market

Why Robinhood?

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. View more

ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy

70%

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151.